Table 1.
Demographics and treatment characteristics.
| Demographics, N=38 patients | |
|---|---|
| Sex | |
| Female | 18 (47.4) |
| Male | 20 (52.6) |
| Race | |
| White | 30 (78.9) |
| Black | 5 (13.2) |
| Other (Asian, American Indian/Alaskan Native or Multiple Race) | 3 (7.9) |
| Ethnicity | |
| Hispanic (Mexican/Chicano, Puerto Rican, South/Central American) | 13 (34.2) |
| Non-Hispanic | 25 (65.8) |
| Primary Diagnosis | |
| B-ALL | 37 (97.4) |
| B-Lymphoblastic Lymphoma | 1 (2.6) |
| Treatment Characteristics, N=39 initial infusion episodes | |
| Age at Infusion (median [range]) | 9.06 years [1.8 – 23.6] |
| Indication for CART | |
| Primary refractory | 5 (12.8) |
| Relapsed disease | 34 (87.2) |
| Relapse 1 | 17 (43.6) |
| Relapse ≥ 2 | 17 (43.6) |
| Pre-CART morphologic blast % (median [range]) | 5 [0 – 98] |
| Prior Therapy | |
| Allogeneic HCT | 10 (25.6) |
| Antigen Directed* | 15 (38.5) |
| Blinatumomab | 12 (30.8) |
| Inotuzumab | 5 (12.8) |
| CD19-CART | 1 (2.5) |
| Bridging Chemotherapy | |
| High intensity | 17 (43.6) |
| Low intensity | 22 (56.4) |
| CRS Max Grade | |
| 0 | 14 (35.9) |
| 1-2 | 19 (48.7) |
| 3-4 | 6 (15.4) |
| Neurotoxicity Max Grade | |
| 0 | 30 (76.9) |
| 1-2 | 5 (12.8) |
| 3-4 | 4 (10.3) |
| carHLH | 5 (12.8) |
| Post-CART Immunomodulatory Treatments | |
| Tocilizumab | 13 (33.3) |
| Corticosteroids | 5 (12.8) |
| Siltuximab | 4 (10.2) |
| Anakinra | 5 (12.8) |
| Ruxolitinib | 1 (2.6) |
Numerical data are presented as the n (%) unless otherwise specified. B-ALL, B-cell acute lymphoblastic leukemia; CART, chimeric antigen receptor T-cell therapy; HCT, hematopoietic cell transplantation; CRS, cytokine release syndrome; carHLH, CAR associated hemophagocytic lymphohistiocytosis; ^morphologic blast % from most recent marrow prior to start of lymphodepleting chemotherapy; *patients may have received more than one antigen directed therapy.